PCORnet to be used for more efficient research on obesity

The Patient-Centered Outcomes Research Institute (PCORI) Board of Governors has approved $9 million to fund two research studies focused on the treatment and prevention of obesity in children and adults. The research teams will use the partnerships and secure data resources of PCORnet, the National Patient-Centered Research Network.

One study will compare the three main methods of weight loss surgery to provide patients and providers with information to help determine the best for their needs. The other will compare the effects of different types of antibiotics on young children’s weight and risk for obesity in later childhood.

The studies will demonstrate PCORnet’s capacity to conduct such observational research faster and with a greater volume of data than is possible through conventional ways of doing research, while ensuring patients’ privacy, according to a release.

In each study, patients’ health records will be maintained securely behind the firewalls of the individual health systems that make up the participating PCORnet partner networks. The research teams will receive general information combined from many records that can’t be linked to individual patients unless the patients agree to share identified information.     

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.